-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on Astria Therapeutics, Maintains $47 Price Target

Benzinga·05/14/2025 14:22:59
Listen to the news
Cantor Fitzgerald analyst Timur Ivannikov reiterates Astria Therapeutics (NASDAQ:ATXS) with a Overweight and maintains $47 price target.